Bempedoic acid is a new class of nonstatin LDL-lowering therapy that has been approved for the European market since April 2020. Bempedoic acid can be used as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease requiring additional lowering of LDL-C.